This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): RiVax
Description: RiVax is a modified subunit of the native ricin toxin which has been genetically engineered to eliminate both its enzymatic activity and its ability to induce vascular leak syndrome (VLS). Complete elimination of both types of toxicity is likely to render this vaccine safe at effective doses and when administered as an intramuscular injection, RiVax induces protective antibody production in mice.
RiVax was originally developed by DOR BioPharma.
In September 2009, DOR BioPharma changed its name to Soligenix.
Soligenix and IDRI
In June 2012, Soligenix announced that it has entered into a collaboration with the Infectious Disease Research Institute (IDRI) of Seattle, WA to develop select biodefense vaccines using IDRIs potent and safe synthetic adjuvants in conjunction with Soligenixs proprietary subunit proteins and thermostability platform known as ThermoVax. The first two developmental objectives of the collaboration include VeloThrax and RiVax.
Soligenix and Emergent
In May 2015, Soligenix announced that it has initiated a development agreement with Emergent BioSolutions to implement a commercially viable, scalable production technology for the RiVax drug substance protein antigen. Soligenix will transfer the manufacturing processes and analytics to Emergent to conduct process development work that could potentially lead to a future...See full deal structure in Biomedtracker
Pink Sheet Weekly Trademark Review April 29, 2014
Additional information available to subscribers only: